Document is current
Any future updates will be listed below
-
Authors
Peterziel, Heike https://orcid.org/0000-0001-9261-7144
Jamaladdin, Nora
ElHarouni, Dina
Gerloff, Xenia F.
Herter, Sonja
Fiesel, Petra
Berker, Yannick https://orcid.org/0000-0002-6707-0834
Blattner-Johnson, Mirjam
Schramm, Kathrin
Jones, Barbara C.
Reuss, David
Turunen, Laura https://orcid.org/0000-0003-0274-4794
Friedenauer, Aileen
Holland-Letz, Tim
Sill, Martin
Weiser, Lena
Previti, Christopher
Balasubramanian, Gnanaprakash
Gerber, Nicolas U. https://orcid.org/0000-0002-1783-631X
Gojo, Johannes
Hutter, Caroline https://orcid.org/0000-0003-2059-4814
Øra, Ingrid https://orcid.org/0000-0002-3931-4125
Lohi, Olli
Kattamis, Antonis
de Wilde, Bram
Westermann, Frank
Tippelt, Stephan
Graf, Norbert https://orcid.org/0000-0002-2248-323X
Nathrath, Michaela
Sparber-Sauer, Monika
Sehested, Astrid
Kramm, Christof M. https://orcid.org/0000-0002-5017-926X
Dirksen, Uta
Kallioniemi, Olli
Pfister, Stefan M.
van Tilburg, Cornelis M. https://orcid.org/0000-0001-5274-910X
Jones, David T. W. https://orcid.org/0000-0002-2036-5141
Saarela, Jani https://orcid.org/0000-0001-7306-7175
Pietiäinen, Vilja https://orcid.org/0000-0003-3125-2406
Jäger, Natalie
Schlesner, Matthias https://orcid.org/0000-0002-5896-4086
Kopp-Schneider, Annette https://orcid.org/0000-0002-1810-0267
Oppermann, Sina https://orcid.org/0000-0002-9101-260X
Milde, Till https://orcid.org/0000-0002-7267-1052
Witt, Olaf
Oehme, Ina https://orcid.org/0000-0002-0827-2356
- License Information
-
More Information
Article History
Received: 5 May 2022
Accepted: 29 November 2022
First Online: 27 December 2022
Competing interests
: C.M.v.T. and I. Øra participated in the advisory boards of Novartis and Bayer. S.M.P. receives funding from Bayer, Pfizer, Eli-Lilly, Roche, Amgen, Astra Zeneca, PharmaMar, Sanofi and Servier in the context of an IMI-2-funded EU project entitled ITCC-P4 (). M.S.-S. participated in advisory boards of SOBI, Roche and Bayer (hemophilia) and receives funding from Bayer for providing data on patients with NTRK-positive infantile fibrosarcoma as a historical cohort. O.W. participated in the advisory boards of Novartis, BMS and Janssen and received research grants from BVD, Day One Therapeutics. The remaining authors declare no competing interests.
